Drug shortage
Clindamycin Phosphate Injection · Baxter Healthcare
FDA drug shortage · Current · updated Apr 7, 2025
Key facts
| Generic name | Clindamycin Phosphate Injection |
|---|---|
| Proprietary name | Clindamycin Phosphate |
| Company | Baxter Healthcare |
| Presentation | Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-9553-50) |
| Dosage form | Injection |
| Strength | 900 mg/50 mL |
| Status | Current |
| Therapeutic category | Anti-Infective |
| Package NDCs | 0338-9553-50 |
| First posted | Mar 21, 2023 |
| Last updated | Apr 7, 2025 |
At a glance
- 1–9 Package NDCs affected
- 10–99 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: